Business
OWC Pharmaceutical Research Corp. Enters Into a Strategic Relationship With Germany-Based mediq Innovation Experts
OWC Pharmaceutical Research Corp. Enters Into a Strategic Relationship With Germany-Based mediq Innovation Experts.
About this update from Owc Pharmaceutical Research Corp
[{"type":"text","content":"\n\n\n\nOWC Pharmaceutical Research Corp. Enters Into a Strategic Relationship With Germany-Based mediq Innovation Experts\n\n\n\n\n\nOWC Pharmaceutical Research Corp. Enters Into a Strategic Relationship With Germany-Based mediq Innovation Experts\nThe Initial Objective of the Collaboration is the Introduction of OWC's Active Cannabinoid-Based Topical Psoriasis Cream to the German Market\nPR Newswire\nPETACH TIKVA, Israel, May 31, 2017\n\n\n\nPETACH TIKVA, Israel, May 31, 2017 /PRNewswire/ --\n\nOWC Pharmaceutical Research Corp. (OTC: OWCP) and mediq Innovation Partners (mediq) are pleased to announce an agreement for the introduction of OWCP's active cannabinoid-based topical psoriasis cream to the German market.\n\n     (Logo: http://mma.prnewswire.com/media/458036/OWC_Logo.jpg )\n\n\nFrankfurt, Germany-based mediq has extensive experience, knowledge and a successful track record in enabling Israel-based companies to penetrate the European markets. mediq's objectives for OWCP will consist of both scientific collaboration and most importantly the development of a commercial market for OWCP's proprietary, active cannabinoid-based topical psoriasis cream in Germany.\n\nCommenting on the collaboration with OWCP, Jan Wende, managing director of mediq stated, \"We're looking forward to initiating our efforts on behalf of OWCP in Europe, starting in our home market of Germany. Since German laws and regulations allow non-smokable forms of medical cannabis, we believe that OWCP's proprietary cannabinoid-based topical psoriasis cream is the right product at the right time. Furthermore, Germany is the largest European healthcare market and therefore offers the perfect platform to gain local evidence and roll out the concept into other European countries. Our initial focus for OWCP is on the German market, however we're excited about the long-term opportunities throughout Europe, a market with a population of over 740 million.\"\n\nAlon Sinai, managing director of OWCP's wholly-owned, Israel-based subsidiary, One World Cannabis, also commented on the collaboration with mediq, \"The German market is a great opportunity for OWCP. Germany, with its population of over 81 million, and a gross domestic product of over US$3.36 trillion is the largest economy in Europe. Also, potentially beneficial to OWCP is Germany's recent...